Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab.
10.3341/jkos.2015.56.9.1359
- Author:
Jong Ha KIM
1
;
Nam Chun CHO
;
Woo Jin KIM
Author Information
1. Department of Ophthalmology, Chonbuk National University Medical School, Jeonju, Korea. alberts123@hanmail.net
- Publication Type:Original Article
- Keywords:
Aflibercept;
Neovascular age-related macular degeneration;
Treatment-resistant
- MeSH:
Humans;
Macular Degeneration*;
Retinaldehyde;
Subretinal Fluid;
Visual Acuity;
Bevacizumab;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2015;56(9):1359-1364
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate outcomes of intravitreal aflibercept in cases resistant to bevacizumab and ranibizumab in neovascular age-related macular degeneration. METHODS: Twenty patients with neovascular age-related macular generation who were resistant to treatment with bevacizumab and ranibizumab were evaluated. After switching to aflibercept the best corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared at baseline and at 1 month after injection. Additionally, changes in the intraretinal fluid, subretinal fluid and pigment epithelial detachment were evaluated. RESULTS: The mean BCVA was 0.83 +/- 0.56 log MAR and the mean CRT was 294.20 +/- 12.99 microm before aflibercept treatment. After switching to aflibercept the mean BCVA was 0.86 +/- 0.61 log MAR with no statistical difference (p = 0.406) and the mean CRT was decreased to 232.45 +/- 12.05 microm (p = 0.011). After 1 month of aflibercept injections, a reduction of intraretinal fluid in 4 eyes (80%), reduction of subretinal fluid in 11 eyes (78.6%) and reduction of pigment epithelial detachment in 5 eyes (50%) were observed. Increases in fluid or new lesions were not observed. CONCLUSIONS: Aflibercept injection appears beneficial in patients with neovascular age-related macular generation who are resistant to bavacizumab and ranibizumab treatment.
